Most Viewed

  • VIDEO FAQ: Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML - N. Daver, MD (6:03) - Posted 04/22
    video
  • VIDEO FAQ: In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients? - D. Pollyea, MD (1:59) - Posted 04/08
    video
  • VIDEO FAQ: What are the advantages and disadvantages of the different FLT3 inhibitors? - A. Perl, MD(1:57) - Posted 04/01
    video
  • e-NEWSLETTER: Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice - N. Daver, MD - Posted 02/17
    text
  • Additional activities...

Supporters

MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com in 2018-2019

  • Agios Pharmaceuticals, Inc.
  • Celgene Corporation
  • Daiichi Sankyo, Inc.
  • Helsinn Healthcare SA
  • Jazz Pharmaceuticals
  • Pfizer Inc.

MediCom Oncology Links

Please visit these other members of the MediCom Oncology family of sites.

Managing MDS Managing Myeloma The Practical Oncologist
Managing Lymphoma Partners in Pancreatic Cancer Emerging Solutions in Pain